Cilostazol, Not Only a Vessel Dilator but Also a Decelerator of Diabetic Nephropathy

Cilostazol，不僅是血管擴張劑，且是糖尿病腎病延緩劑

李文欽(Wen-Chin Lee) ； 李彗禎(Huei-Jane Lee)

《童綜合醫學雜誌》 8卷1期 (2014/06) Pp. 1-5

摘要

Cilostazol，一種磷酸雙酯酶抑制劑，可經由增加組織cAPM而預防血小板凝集及擴張血管。近來研究指出cAMP會在腎病發展過程中調節一些訊息傳遞路徑而改變有絲分裂、發炎及包外基質合成，因此cilostazol被指出在streptozotocin誘導的糖尿病鼠腎臟中，可有效改善腎病及活性氧活性；另外也可改善血脂。Cilostazol在降低活性氧及改善血脂的特性可能是延緩糖尿病腎病變進程的因素。

關鍵字

氧化壓力 ； 糖尿病腎病變

並列摘要

Cilostazol, a specific inhibitor of phosphodiesterase 3, can prevent platelet aggregation and dilate blood vessels via an increase in cyclic adenosine monophosphate (cAMP). Recent studies suggested that cAMP regulates several signaling pathways involved in the development and progression of renal disease, including mitogenesis, inflammation, and extracellular matrix synthesis. Cilostazol administration in streptozotocin-induced diabetic rats was reported to improve diabetic nephropathy as well as significantly decrease reactive oxygen species activity in the kidneys. In addition, cilostazol improved the serum cholesterol, triglyceride, and low density lipoprotein-cholesterol levels. Transforming growth factor-b and nuclear factor-kB are up-regulated in diabetic kidneys, but cilostazol treatment reduced the expression of these proteins. In conclusion, the ability of cilostazol to reduce oxidative stress and improve dyslipidemia may prevent the progression of diabetic nephropathy and diminish the risk of cardiovascular disease in diabetic patients.

並列關鍵字

Cilostazol ； oxidative stress ； diabetic nephropathy ； TGF-β ； NF-κB